close
Patient InformationDownloadPrescribing InformationDownloadFor Healthcare Providers

What Is EGRIFTA WR™?

EGRIFTA WR™ has over 10 years of established safety.

EGRIFTA WR™ is a prescription medicine used to reduce the excess stomach-area (abdominal) fat in adults with HIV and lipodystrophy.* EGRIFTA WR™ is a growth hormone-releasing factor (GHRF) analog.
* EGRIFTA WR™ is not for weight loss management. The long-term safety of EGRIFTA WR™ on the heart and blood vessels (cardiovascular) is not known. It is not known whether taking EGRIFTA WR™ helps improve how well you take your antiretroviral medications. It is not known if EGRIFTA WR™ is safe and effective in children; do not use EGRIFTA WR™ in children.

How does EGRIFTA WR™ work?

Growth hormone

Many people with HIV have lower levels of growth hormone in their bodies than normal.

Growth hormone
Human figure with excess abdominal fat
  • EGRIFTA WR™ is a GHRF analog, which causes the body to make more of its own growth hormone.
  • By increasing levels of growth hormone, EGRIFTA WR™ helps to restore the body’s normal metabolic processes, and reduce EVAF.
Learn how to take EGRIFTA WR™.
See Step-by-Step Instructions

Proven results through rigorous clinical trials

  • Tesamorelin, the active ingredient in EGRIFTA WR™, was studied in two clinical trials in adults with HIV and lipodystrophy who had excess visceral abdominal fat.
  • Each trial lasted 6 months, with an additional 6-month extension phase, for a total of 1 year of treatment.
Tesamorelin significantly reduced excess visceral abdominal fat in both clinical trials.
Down
Trial 1
%

average reduction at 6 months

Down
Trial 2
%

average reduction at 6 months

Arrow going down then right

People who used tesamorelin continuously for 1 year maintained their results over this period.

Arrow going down then right then up

Excess visceral abdominal fat returned when tesamorelin was stopped after 6 months of therapy.

Losing too much lean body mass may negatively affect your health

People with HIV may have concerns about losing healthy muscle mass, also known as lean body mass. During clinical trials, people who used tesamorelin did not lose lean body mass.
EGRIFTA WR™ may increase lean body mass by up to 5 pounds.
Talk to your healthcare provider to find out if EGRIFTA WR™ can help.
Coming Soon

What is EGRIFTA WR™ (tesamorelin) for injection?

  • EGRIFTA WR™ is a prescription medicine used to reduce the excess stomach-area (abdominal) fat in adults with HIV and lipodystrophy.
  • EGRIFTA WR™ is a growth hormone-releasing factor (GHRF) analog.
  • EGRIFTA WR™ is not for weight loss management.
  • The long-term safety of EGRIFTA WR™ on the heart and blood vessels (cardiovascular) is not known.
  • It is not known whether taking EGRIFTA WR™ helps improve how well you take your antiretroviral medications.
  • It is not known if EGRIFTA WR™ is safe and effective in children; do not use EGRIFTA WR™ in children.

You should not take EGRIFTA WR™ if you:

  • Have a pituitary gland tumor, surgery, or other problems related to your pituitary gland, or have had radiation treatment to your head or head injury.
  • Have active cancer.
  • Are allergic to tesamorelin or any of the ingredients in EGRIFTA WR™.
  • Are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA WR™ and talk with your healthcare provider.
  • Are less than 18 years of age.

Before using EGRIFTA WR™ tell your healthcare provider if you:

  • Have or have had cancer.
  • Have problems with blood sugar or diabetes.
  • Have scheduled heart or stomach surgery.
  • Have breathing problems.
  • Are breastfeeding or plan to breastfeed.
  • Are taking any other prescription and non-prescription medicines, vitamins, and herbal supplements.

EGRIFTA WR™ may cause serious side effects including:

  • Increased risk of new cancer in adults with HIV or your cancer coming back (reactivation). Stop using EGRIFTA WR™ and inform your healthcare provider if any cancer symptoms come back.
  • Increased levels of your insulin-like growth factor-1 (IGF-1). Your healthcare provider will do blood tests to check your IGF-1 levels while you are taking EGRIFTA WR™.
  • Serious allergic reaction such as rash or hives anywhere over the body or on the skin, swelling of the face or throat, shortness of breath or trouble breathing, fast heartbeat, feeling of faintness or fainting, itching and reddening or flushing of the skin. If you have any of these symptoms, stop using EGRIFTA WR™ and get emergency medical help right away.
  • Swelling or fluid retention. Call your healthcare provider if you have swelling, an increase in joint pain, or pain or numbness in your hands or wrists.
  • Increase in blood sugar (glucose) or diabetes.
  • Injection site reactions. Injection site reactions are a common side effect of EGRIFTA WR™ but may sometimes be serious.
  • Increased risk of death in people who have critical illness because of heart or stomach surgery, trauma or serious breathing (respiratory) problems has been reported after treatment with therapeutic doses of growth hormone.

The most common side effects of EGRIFTA WR™ include:

  • Pain in legs and arms
  • Muscle pain

These are not all the possible side effects of EGRIFTA WR™. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or to TPS logo toll-free at 1-833-23THERA (1-833-238-4372).

This information is not intended to replace discussions with your doctor. For additional information about EGRIFTA WR™, see the Patient Information and Patient Instructions for Use, and talk to your doctor. For more information about EGRIFTA WR™ contact TPS logo toll-free at 1-833-23THERA (1-833-238-4372).